Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells

被引：39

作者：

Toshimitsu, H

Hashimoto, K

Tangoku, A

Iizuka, N

Yamamoto, K

Kawauchi, S

Oga, A

Furuya, T

Oka, M

Sasaki, K

机构：

[1] Yamagata Univ, Sch Med, Dept Pathol 2, Ube, Yamaguchi 7558505, Japan

[2] Yamagata Univ, Sch Med, Dept Surg 2, Ube, Yamaguchi 7558505, Japan

[3] Yamagata Univ, Sch Med, Dept Bioregulatory Funct, Ube, Yamaguchi 7558505, Japan

来源：

CANCER LETTERS | 2004年 / 211卷 / 01期

关键词：

acquired CDDP-resistant cell line; comparative genomic hybridization; cDNA microarray; ribosomal protein;

D O I：

10.1016/j.canlet.2004.01.038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To clarify the molecular basis of acquired cisplatin (CDDP) resistance in esophageal squamous cell carcinoma (ESCC), we used cDNA microarray technology. A CDDP-resistant cell line (YES-2/CDDP), which shows a 7.5-fold increase in resistance to CDDP and a 3-fold decrease in CDDP accumulation compared with the parental YES-2 ESCC cell line, was generated from YES-2 by exposure to increased concentrations of CDDP. By cDNA microarray analysis, we identified 44 genes with significantly different expression levels between YES-2/CDDP and YES-2 cells. Interestingly, 15 of these 44 genes encoded ribosome-related proteins, almost all of which were underexpressed in YES-2/CDDP cells. Our present data suggest that many ribosome-related genes may be involved in the acquired resistance to CDDP in ESCC and that such information may allow us to better understand the mechanism of CDDP resistance. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：69 / 78

页数：10

共 61 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2]

ANDREWS PA, 1988, CANCER RES, V48, P68

[3]

Chen F W, 1999, Int Rev Immunol, V18, P429, DOI 10.3109/08830189909088492

[4]

Dabholkar M, 1996, Cancer Chemother Biol Response Modif, V16, P88

[5] MESSENGER-RNA LEVELS OF XPAC AND ERCC1 IN OVARIAN-CANCER TISSUE CORRELATE WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY [J].

DABHOLKAR, M ;

VIONNET, J ;

BOSTICKBRUTON, F ;

YU, JJ ;

REED, E .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) :703-708

[6] Enhanced resistance of HeLa cells to cisplatin by overexpression of γ-glutamyltransferase [J].

Daubeuf, S ;

Leroy, P ;

Paolicchi, A ;

Pompella, A ;

Wellman, M ;

Galteau, MM ;

Visvikis, A .

BIOCHEMICAL PHARMACOLOGY, 2002, 64 (02) :207-216

[7] DNA microarrays in drug discovery and development [J].

Debouck, C ;

Goodfellow, PN .

NATURE GENETICS, 1999, 21 (Suppl 1) :48-50

[8]

FLOTOW H, 1992, J BIOL CHEM, V267, P3074

[9]

Furuya T, 1997, CYTOMETRY, V29, P173

[10] CELLULAR ACCUMULATION OF THE ANTICANCER AGENT CISPLATIN - A REVIEW [J].

GATELY, DP ;

HOWELL, SB .

BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1171-1176

← 1 2 3 4 5 6 7 →